Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
June 2025
Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, Phase 3 trial
Lancet Respir Med 2020;8:963–74 DOI: 10.1016/S2213-2600(20)30318-0.
Khanna et al. evaluated tocilizumab in patients with early diffuse cutaneous systemic sclerosis in the focuSSced trial. The primary endpoint of improved skin fibrosis was not met, but a key secondary outcome showed that tocilizumab significantly preserved lung function compared with placebo.